Cargando…

Towards On-Demand E. coli-Based Cell-Free Protein Synthesis of Tissue Plasminogen Activator

Stroke is the leading cause of death with over 5 million deaths worldwide each year. About 80% of strokes are ischemic strokes caused by blood clots. Tissue plasminogen activator (tPa) is the only FDA-approved drug to treat ischemic stroke with a wholesale price over $6000. tPa is now off patent alt...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Seung-Ook, Nielsen, Gregory H., Wilding, Kristen M., Cooper, Merideth A., Wood, David W., Bundy, Bradley C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6632163/
http://dx.doi.org/10.3390/mps2020052
_version_ 1783435681790427136
author Yang, Seung-Ook
Nielsen, Gregory H.
Wilding, Kristen M.
Cooper, Merideth A.
Wood, David W.
Bundy, Bradley C.
author_facet Yang, Seung-Ook
Nielsen, Gregory H.
Wilding, Kristen M.
Cooper, Merideth A.
Wood, David W.
Bundy, Bradley C.
author_sort Yang, Seung-Ook
collection PubMed
description Stroke is the leading cause of death with over 5 million deaths worldwide each year. About 80% of strokes are ischemic strokes caused by blood clots. Tissue plasminogen activator (tPa) is the only FDA-approved drug to treat ischemic stroke with a wholesale price over $6000. tPa is now off patent although no biosimilar has been developed. The production of tPa is complicated by the 17 disulfide bonds that exist in correctly folded tPA. Here, we present an Escherichia coli-based cell-free protein synthesis platform for tPa expression and report conditions which resulted in the production of active tPa. While the activity is below that of commercially available tPa, this work demonstrates the potential of cell-free expression systems toward the production of future biosimilars. The E. coli-based cell-free system is increasingly becoming an attractive platform for low-cost biosimilar production due to recent developments which enable production from shelf-stable lyophilized reagents, the removal of endotoxins from the reagents to prevent the risk of endotoxic shock, and rapid on-demand production in hours.
format Online
Article
Text
id pubmed-6632163
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66321632019-08-19 Towards On-Demand E. coli-Based Cell-Free Protein Synthesis of Tissue Plasminogen Activator Yang, Seung-Ook Nielsen, Gregory H. Wilding, Kristen M. Cooper, Merideth A. Wood, David W. Bundy, Bradley C. Methods Protoc Benchmark Stroke is the leading cause of death with over 5 million deaths worldwide each year. About 80% of strokes are ischemic strokes caused by blood clots. Tissue plasminogen activator (tPa) is the only FDA-approved drug to treat ischemic stroke with a wholesale price over $6000. tPa is now off patent although no biosimilar has been developed. The production of tPa is complicated by the 17 disulfide bonds that exist in correctly folded tPA. Here, we present an Escherichia coli-based cell-free protein synthesis platform for tPa expression and report conditions which resulted in the production of active tPa. While the activity is below that of commercially available tPa, this work demonstrates the potential of cell-free expression systems toward the production of future biosimilars. The E. coli-based cell-free system is increasingly becoming an attractive platform for low-cost biosimilar production due to recent developments which enable production from shelf-stable lyophilized reagents, the removal of endotoxins from the reagents to prevent the risk of endotoxic shock, and rapid on-demand production in hours. MDPI 2019-06-21 /pmc/articles/PMC6632163/ http://dx.doi.org/10.3390/mps2020052 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Benchmark
Yang, Seung-Ook
Nielsen, Gregory H.
Wilding, Kristen M.
Cooper, Merideth A.
Wood, David W.
Bundy, Bradley C.
Towards On-Demand E. coli-Based Cell-Free Protein Synthesis of Tissue Plasminogen Activator
title Towards On-Demand E. coli-Based Cell-Free Protein Synthesis of Tissue Plasminogen Activator
title_full Towards On-Demand E. coli-Based Cell-Free Protein Synthesis of Tissue Plasminogen Activator
title_fullStr Towards On-Demand E. coli-Based Cell-Free Protein Synthesis of Tissue Plasminogen Activator
title_full_unstemmed Towards On-Demand E. coli-Based Cell-Free Protein Synthesis of Tissue Plasminogen Activator
title_short Towards On-Demand E. coli-Based Cell-Free Protein Synthesis of Tissue Plasminogen Activator
title_sort towards on-demand e. coli-based cell-free protein synthesis of tissue plasminogen activator
topic Benchmark
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6632163/
http://dx.doi.org/10.3390/mps2020052
work_keys_str_mv AT yangseungook towardsondemandecolibasedcellfreeproteinsynthesisoftissueplasminogenactivator
AT nielsengregoryh towardsondemandecolibasedcellfreeproteinsynthesisoftissueplasminogenactivator
AT wildingkristenm towardsondemandecolibasedcellfreeproteinsynthesisoftissueplasminogenactivator
AT coopermeridetha towardsondemandecolibasedcellfreeproteinsynthesisoftissueplasminogenactivator
AT wooddavidw towardsondemandecolibasedcellfreeproteinsynthesisoftissueplasminogenactivator
AT bundybradleyc towardsondemandecolibasedcellfreeproteinsynthesisoftissueplasminogenactivator